Please assess the completion status of the following clinical trial:

Trial Title: Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female subjects aged ≥18 years~* Confirmed diagnosis of SCLC by histology or cytology, preferably including the presence of neuroendocrine features by immunohistochemistry~* Progression during or after prior first- or second-line chemotherapy and eligible to receive topotecan therapy~* At least 1 target lesion that is measurable by RECIST, Version 1.1~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2~* Adequate organ function~Key Exclusion Criteria:~* Presence of brain metastases requiring immediate treatment with radiation therapy or steroids.~* Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure~* Known history of stroke or cerebrovascular accident within 6 months prior to enrollment~* Other uncontrolled serious chronic disease or conditions that in the investigator's opinion could affect compliance or follow-up in the protocol~* Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment or previous radiotherapy to the target lesion sites~* Receipt of any systemic chemotherapy regimen within 4 weeks prior to enrollment or a noncytotoxic investigational medication within 2 weeks prior to enrollment~* History of topotecan treatment for SCLC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b (Type: EXPERIMENTAL): Patients in Parts 2a and 2b were randomized 1:2 to placebo. Patients received placebo administered IV once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of placebo on Days 1 to 5, patients received IV topotecan (1.5 mg/m²).
- Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a (Type: EXPERIMENTAL): Patients in Part 2a were randomized 2:1 to trilaciclib. Patients received trilaciclib (240 mg/m²) administered IV once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (0.75 mg/m²).
- Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b (Type: EXPERIMENTAL): Patients in Part 2b were randomized 2:1 to trilaciclib. Patients received trilaciclib (240 mg/m²) administered IV once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (1.5 mg/m²).
- Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 1 (Type: EXPERIMENTAL): Patients received trilaciclib (200 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (1.50 mg/m²).
- Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 1 (Type: EXPERIMENTAL): Patients received trilaciclib (200 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (1.25 mg/m²).
- Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 1 (Type: EXPERIMENTAL): Patients received trilaciclib (200 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (0.75 mg/m²).
- Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 1 (Type: EXPERIMENTAL): Patients received trilaciclib (240 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (0.75 mg/m²).
- Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 1 (Type: EXPERIMENTAL): Patients received trilaciclib (280 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (0.75 mg/m²).
- Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 1 (Type: EXPERIMENTAL): Patients received trilaciclib (240 mg/m²) administered intravenously (IV) once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients received IV topotecan (1.0 mg/m²).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy